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Abstract
Background: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell
cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV
(DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis
or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS.
Methods/Results: Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a
bioassay, using K562 cells and
51Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative
flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve
assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230
controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significant difference in NK cell
counts between cases and controls. Percent CD2+ lymphocytes (T cells and NK cells) positive for DPPIV/C26 was elevated in
CFS cases, but there was a decrease in the number of molecules (rMol) of DPPIV/C26 expressed on T cells and NK cells and a
decrease in the soluble form of the enzyme in serum. Analyses by ROC curves indicated that all three measurements of
DPPIV/CD26 demonstrated potential as biomarkers for CFS. None of the DPPIV/C26 assays were significantly correlated with
NKCC.
Conclusions: By ROC analysis, NKCC and three methods of measuring DPPIV/C26 examined in this study had potential as
biomarkers for CFS. Of these, NKCC, %CD2+CD26+ lymphocytes and rMol CD26/CD2+ lymphocyte, required flow cytometry,
fresh blood and access to a high complexity laboratory. Soluble DPPIV/C26 in serum is done with a standard ELISA assay, or
with other soluble factors in a multiplex type of ELISA. Dipeptidyl peptidase IV on lymphocytes or in serum was not
predictive of NKCC suggesting that these should be considered as non-redundant biomarkers. Abnormalities in DPPIV/CD26
and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of
CFS.
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Introduction
Chronic Fatigue Syndrome (CFS) is characterized by persistent
and unexplained fatigue resulting in severe impairment in daily
function and is defined by symptoms, disability, and exclusion of
medical and psychiatric conditions that could explain the fatigue
[1,2]. Population-based studies estimated the prevalence of CFS at
0.23% to 0.41% [3,4]. Costs to the US economy were estimated at
$9 billion in lost productivity and up to $24 billion dollars in health
care expenditures annually [5–7]. Complications and co-morbidity
can be severe. For example, CFS was associated with chronic or
episodic cardiovascular and autonomic dysfunction [8]. Recent
results from our group demonstrated reduced stroke volume and
cardiac output in more severely afflicted CFS patients [9]. Reports
suggested increased risk of cancer as well as suicide [10,11]. CFS
affects all ethnic groups and socio-economic strata of society
though at least 2 to 4 times as many women as men suffer from
this illness [3,12,13]. Diagnosis using the case definition [1]
requires the exclusion of any other medical explanation for these
symptoms, yielding an inefficient, slow, error prone process. This
is also costly because current clinical diagnosis typically involves
tertiary care specialists.
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and affects several of the body’s main regulatory systems. There is
a considerable literature describing immune dysfunction in CFS
[14–16], although reviews of the immunology of CFS noted that
universal agreement of immunological abnormalities had not been
achieved, in no small part due to differences in methodologies,
case definition and study quality [17,18]. However, redundant
reports support 1) reduced function of natural killer (NK) cells
[14,19] with deficiencies of perforin and granzymes in both NK
cells and CD8 T cells [20]; 2) inflammation [21,22]; 3) altered
cytokine profiles [9,10] with elevation of proinflammatory
cytokines [11,12] and Th2 (T helper cell type 2) polarization
[11,13]; and 4) chronic lymphocyte activation [14,16].
Current research efforts are directed toward identifying an
individual marker or combination of markers sufficiently associ-
ated with CFS to facilitate objective diagnosis and management of
CFS. Previously we reported that CFS patients with poor NK
function had more fatigue, less vigor, more daytime dysfunction,
and more cognitive impairment. Those results provided prelim-
inary evidence in support of using NKCC as subgroup marker for
disease severity in CFS [23].
Present on the surface of many cells including lymphocytes,
DPPIV/CD26 is a transmembrane glycoprotein and a serine
peptidase that spits proline dipeptides from the N-terminus of
polypeptides, including chemokines and neuropeptides. An
enzymatically active soluble form is found in serum. We have
observed an elevated proportion of lymphocytes expressing this
activation marker in CFS patients as compared to controls [14].
No widely accepted laboratory tests are available for the
diagnosis or prognosis of CFS. This study sought to determine the
accuracy by which measurements of NKCC or DPPIV/CD26
distinguished between subjects with the clinically derived diagnosis
of CFS and matched healthy controls.
Methods
Objectives
Prior work indicated defective NK cell function and a high
percent of T cells and NK cells expressing the activation marker
DPPIV/CD26 in CFS cases. The aim of this study was to
determine the potential of NKCC and DPPIV/CD26 as
biomarkers for CFS.
Participants
Chronic fatigue syndrome patients (age 18 to 60, mean age 44;
83% female) were drawn from the University of Miami Miller
School of Medicine CFS and Immunodeficiency Clinic after they
were diagnosed with CFS using the CDC clinical diagnostic
criteria [1,2] (Table 1). All were participants in research studies
(NIH, Chronic Fatigue and Immunodeficiency Syndrome Associ-
ation (CFIDS) or University of Miami). Exclusion criteria included
any active medical condition that could explain the presence of
chronic fatigue, including diabetes, the current use of immuno-
modulatory or antibiotic medications, and a past or present
psychiatric diagnosis of psychosis (e.g., schizophrenia), dementia,
major depressive disorder with psychotic or melancholic features,
bipolar disorder, anorexia or bulimia nervosa, or alcohol/
substance abuse within two years of the onset of the fatigue or
anytime thereafter. The CFS subjects were studied at 2 to 25 years
after onset of symptoms, with an average onset of 10 years.
Healthy controls (Table 1) (age 23–74, mean age 41, 86% female)
were drawn from University of Miami, NIH or CFIDS funded
studies. Each completed a medical and psychiatric history that
included medications and alcohol/substance abuse. Those with
active medical or psychiatric conditions, immunomodulating
medications or alcohol/substance abuse were excluded.
Description of Procedures or Investigations Undertaken
Blood Collection. Morning blood samples were collected.
For lymphocyte function assays and flow cytometry, sodium
heparin tubes were used. The samples were held at room
temperature and delivered to the laboratory within 4 hours. For
complete blood counts, the blood was collected into ethylene
diamine tetra acetic acid and delivered to the laboratory within
4 hours. Serum was separated from blood clot within 4 hours of
collection into red stopper tube and stored at 220uC until assayed.
Natural killer cell cytotoxicity. The bioassay for NKCC
was performed using whole blood within 8 hours of collection in a
chromium release assay as previously described [24]. The NK
sensitive erythroleukemic K562 cell line was used as the target cell.
The assay was done in triplicate at four target-to-effector cell ratios
with 4-hour incubation. The % cytotoxicity at each target-to-
effector ratio and number of CD3-CD56+ (NK) cells per unit of
blood was used to express the results as % cytotoxicity at a target-
to-effector cell ratio of 1:1.
Determination of Lymphocyte Subsets and Assessment
of Cell Surface Protein Concentrations by Quantitative
Fluorescence. For the assessment of lymphocyte subsets, and
the quantitative fluorescence intensity studies of cell surface
antigen, a whole blood lysis method was used [25]. Whole blood
samples were stained in 4 color combinations, with optimized
(saturating) concentrations of antibodies, erythrocytes were lysed
and the cell fixed with the Optilyse C reagent (Beckman-Coulter
Corp., Hialeah, FL). Determination of lymphocyte, monocyte and
granulocyte populations was determined using light scatter and
back gating on fluorescence for the CD45 bright and CD14
Table 1. Natural killer cell cytotoxicity and dipeptidyl peptidase IV/CD26 in chronic fatigue syndrome cases
a compared to
controls
b.
Variable
Number of CFS
Cases Median (25–75
th percentile)
Number of Healthy
Controls Median (25–75
th percentile) p
NKCC% 176 12 (8–21) 230 28 (20–37) .000
% CD26+CD2+ Cells 75 61 (55–66) 100 52 (47–59) .000
sCD26 in Serum (ng/ml) 73 489 (396–643) 122 671 (496–871) .000
rMol CD26/CD2+ Cell 77 3625 (2844–4633) 102 4388 (3600–5388) .001
a.80% female, average age 48;
b.80% female, average age 47.
doi:10.1371/journal.pone.0010817.t001
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cytometer. The isotype control was the reference for negative
events. Spectral compensation was established daily. Quality
control included optimization for lymphocyte recovery, purity of
gate of analysis, lymphosum, and replicate determinations.
Phycoerythrin (PE) labeled antibodies were used for quantitative
fluorescence determinations and the median fluorescence intensity
value was entered into a least squares linear regression equation
derived from analysis of the QuantiBrite fluorescence intensity
standards (Beckton Dickenson, San Jose, CA). This permitted
conversion from fluorescence intensity values to median numbers
of molecules PE bound per cell (relative numbers of molecules
protein expressed per cell at saturating concentrations of antibody;
rMol/cell). This technique allowed us to determine the relative (r)
number of molecules (Mol) of CD26 on CD2+ lymphocytes (T
cells and NK cells) (Figure S1).
Assay of Soluble CD26. Soluble CD26 in serum was assayed
with an ELISA kit from Bender MedSystems (Vienna, Austria).
This assay has a sensitivity of 7.26 ng/ml and precision of 4.6%.
Ethical issues. All subjects signed an informed consent
approved by the University of Miami Institutional Review
Board. Participants were English speaking with at least an 8
th
grade education to ensure they were able to comprehend the
informed consent as well as read and complete the questionnaires.
Statistical Methods. The nonparametric Mann-Whitney
test was used to determine the magnitudes of between-group
differences. The nonparametric Spearman test was used to
determine correlations. Values of p,0.05 were considered
statistically significant. The diagnostic accuracy of biomarkers
was assessed in terms of true positive (sensitivity) versus true
negative (1-specificity) using nonparametric receiver operating
characteristics (ROC) analyses [26] available in the Statistical
Package for Social Sciences (SPSS) software for Windows (SPSS
Inc, Chicago, IL). The nonparametric ROC plot uses all of the
data, makes no parametric assumptions and provides unbiased
estimates of sensitivity and specificity, indicating the ability of a test
to discriminate between two alternate states of health, in this case,
CFS cases and healthy controls. The calculation of the area under
the curve (AUC) provides a convenient single number. An
AUC.0.5 indicates that the test shows no difference between
the two groups while AUC=1.0 is found if the test gives a perfect
separation between groups. The coordinates of the curves (COC),
which provide the entire spectrum of sensitivity/specificity pairs
and a complete picture of test accuracy, are given in
Supplementary Files for each ROC plot.
Results
Natural killer cell cytotoxicity
The NKCC values were significantly lower in cases than
controls (p,.000) (Table 1). Numbers of NK cells were not
different between CFS and controls. The values for CD3-CD56+
lymphocytes/cumm (expressed as median (25
th–75
th percentile)
were: 176 (134–256) for CFS and 236 (151–336) for controls.
According to the nonparametric ROC curve for 406 samples, as
shown in Figure 1, NKCC was a good predictor of CFS status.
Smaller values for NKCC indicated evidence for a positive actual
state (CFS).The area under the curve (AOC) is shown in Table 2.
The coordinates of the curve (COC) are given in Table S1.
Dipeptidyl peptidase IV/CD26
We measured this peptidase on cell surfaces and in serum in a
subset of samples for which we had assayed NKCC. The results
shown in Table 1, with CFS compared to controls, indicated an
elevation of the percent of CD26+ CD2+ lymphocytes, but a
decrease in the number of molecules of CD26 on T cells and NK
cells and a decrease in the soluble form of CD26 in serum. ROC
curve analyses and AUC, shown in Table 2 and Figures 2, 3, and 4
indicated that all three measures of CD26 have potential as
biomarkers for CFS (see COCs in Tables S2, S3, and S4). The
qualitative flow cytometry assay for proportion of CD26+CD2+
lymphocytes and the ELISA assay of sCD26 in serum were good
predictors. The quantitative flow method for concentration of
CD26 on CD2+ lymphocytes was less precise. Spearman analyses
showed that none of the CD26 assays were significantly correlated
with NKCC (data not shown).
Discussion
Data from this and earlier studies gave credible support to
diminished NKCC function in CFS. These effector cells of the
innate immune system have an important role in antiviral,
antibacterial, and antitumor immunity, but were deficient as
measured by direct cytolysis of target cells, and as determined by
measurement of intra cellular lytic proteins [14,20]. In 60 to 80%
of published samples, CFS presented with acute onset of illness,
with systemic symptoms similar to influenza infection that did not
subside [14]. The sudden onset, the symptoms of myalgia,
arthralgia, sore throat and tender lymphadenopathy prompted a
theory of infection induced illness [14,27]. Published reports both
support and deny associated microbial infections, reactivation of
latent herpes virus infections and/or retrovirus infections in CFS
[28–35]. Of interest is the finding by Glaser and colleagues that
the adverse immunologic effects of persistent infections with
Epstein Barr Virus (EBV) did not require viral DNA synthesis
[36]. Some published work suggested the possibility of elevated
risk for cancer in patients with CFS [10–11], though to date there
Figure 1. ROC analyses were used to evaluate NKCC as a
predictor of CFS. The nonparametric ROC plot (blue curve) indicated
the ability of NKCC to discriminate between CFS cases and healthy
controls. Smaller values for NKCC were associated with CFS cases. The
45 degree line (green) indicates the theoretical plot of a test with no
discrimination between CFS and controls.
doi:10.1371/journal.pone.0010817.g001
Biomarkers in CFS
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10817has been no long term natural history study to accurately assess
this risk.
Previously, we showed that the proportion of lymphocytes (NK
cells and T cells) expressing CD26 is elevated in CFS cases [14]. In
the present study, we found the density of DPPIV/CD26 on
lymphocyte surfaces and the concentration of the enzyme in
plasma is reduced in CFS subjects, compared to controls. We
hypothesize that this reduction is due to chronic lymphocyte
activation in CFS patients. The present study adds to the evidence
of loss of innate immune function and chronic immune activation,
resulting from the long term presence of antigenic stimulus, either
self or foreign. Compared to healthy controls, chronic hepatitis C
patients had significantly lower serum soluble CD26 levels [37]. In
another study, acute, self-limiting infection with live influenza
vaccine and chronic infection with persistent antigen, such as with
cytomegalovirus (CMV), EBV or human immunodeficiency virus
(HIV), was compared using multi-parameter flow cytometry and
tetramer technology. These analyses identified a unique pattern of
high density DPPIV/CD26 expression among influenza-specific
CD8 T cells, but not among CD8 T cells specific for CMV, EBV
(three different epitopes) or HIV [38]. These findings were
interpreted as indicating that expression of CD26 (high) is
characteristic of a memory cell, present in acute infection but
not in chronic infection.
Dipeptidyl peptidase IV/CD26 cleaves N-terminal X-Pro
dipeptides from peptides. The peptidase controls the in vivo half-
life of the proinflammatory chemokine stromal cell-derived factor-
1 (SDF-1). Mice deficient in DPPIV/CD26 exhibited increased
levels of circulating active SDF-1, associated with increased
numbers of SDF-1 receptor (CXCR4)-positive cells infiltrating
Table 2. ROC curve analysis: Area Under the Curve (AUC) for natural killer cell cytotoxicity and dipeptidyl peptidase IV/CD26 in
chronic fatigue syndrome cases compared to controls.
Variables Area Std. Error
a Asymptotic Sig.
b
Asymptotic 95%
Confidence Interval
Lower Bound Upper Bound
NKCC% .776 .024 .000 .729 .823
CD2+CD26+% .746 .037 .000 .674 .818
sCD26 ng/ml .732 .036 .000 .652 .794
rMolCD26/CD2+ cell .650 .042 .001 .568 .733
aUnder the nonparametric assumption;
bNull hypothesis: true area=0.5.
doi:10.1371/journal.pone.0010817.t002
Figure 2. ROC analyses were used to evaluate %CD26+CD2+
lymphocytes as a predictor of CFS. The nonparametric ROC plot
(purple curve) indicated the ability of %CD26+CD2+ lymphocytes to
discriminate between CFS cases and healthy controls. Larger values for
%CD26+CD2+ lymphocytes were associated with CFS cases. The 45
degree line (green) indicates the theoretical plot of a test with no
discrimination between CFS and controls.
doi:10.1371/journal.pone.0010817.g002
Figure 3. ROC analyses were used to evaluate serum dipeptidyl
peptidase IV/CD26 as a predictor of CFS. The nonparametric ROC
plot (red curve) indicated the ability of serum dipeptidyl peptidase IV/
CD26 to discriminate between CFS cases and healthy controls. Smaller
values were associated with CFS cases. The 45 degree line (green)
indicates the theoretical plot of a test with no discrimination between
CFS and controls.
doi:10.1371/journal.pone.0010817.g003
Biomarkers in CFS
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plasma levels of DPPIV/CD26 from rheumatoid arthritis patients
were significantly decreased when compared to those from
osteoarthritis patients and inversely correlated with C-reactive
protein levels. They postulated that decreased circulating soluble
DPPIV/CD26 levels in arthritis may influence DPPIV/CD26-
mediated regulation of the chemotactic SDF-1/CXCR4 axis.
These patients have elevated number of T cells expressing
DPPIV/CD26 and reduced DPPIV enzymatic activity and
DPPIV/CD26 antigen in plasma compared to controls [39,40].
Dipeptidyl peptidase IV/CD26 causes the degradation of
glucagon-like peptide 1 (GLP-1), an incretin hormone [41].
Inhibitors of DPPIV/CD26 such as sitagliptin, which prevent
the degradation of GLP-1 [42], are now marketed for the
treatment of type 2 diabetes mellitus (T2DM). Considering that
DPPIV/CD26 has a key role in immune regulation as a T cell
activation molecule and in immune-mediated disorders, it is
noteworthy that the effects of inhibition of DPPIV/CD26 on the
immune system have not been extensively investigated. There are
reports that infections were increased after sitagliptin treatment
[43]. So far, only routine laboratory safety variables have been
measured in published randomized controlled trials.
Administration of DPPIV/C26 inhibitors for the treatment of
T2DM patients could influence immune function, including
NKCC. A study of CD26 gene knockout mice concluded that
DPPIV/C26 contributes to the regulation of development,
maturation and migration of CD4 T, NK and NKT cells,
cytokine secretion, T cell-dependent antibody production and
immunoglobulin isotype switching of B cells [44]. An initial
diagnosis of CFS would not be made in the patient with obvious
T2DM. However, the frequency of development of T2DM after
diagnosis of CFS is not known–nor is the effects of a DPPIV/C26
inhibitor in the CFS patient.
Duration of illness typically exceeds 10 years. Persistence may
involve complex interaction of immune, autonomic and neuroen-
docrine regulation and remains poorly understood. It is important
to recall that the associated chronic inflammation can have
important consequences on energy metabolism by promoting
insulin resistance [45]. This chronic inflammatory state would also
support a concurrent low-grade Th1 response by inhibiting the
protective effects of T regulatory cell subset via increased IL-6
expression. The decreased NKCC and the abnormal DPPIV/C26
manifestations in CFS would be compatible with the hypothesis
that the immune system of affected individuals is biased towards a
T- helper (Th) 2 type, or humoral immunity-oriented cytokine
pattern.
The data obtained on NK cell function, immune activation and
DPPIV/C26 on cell surfaces and in serum, are consistent with a
viral etiology for CFS. The elevated proportion of activated CD4
and CD8 T cells and defective NKCC in CFS cases suggests that
T cells are metabolically limited in performing their helper
function. The abnormalities observed may have applications with
other complex, chronic and poorly understood illnesses, including
fibromyalgia, gulf war illness, rheumatologic disorders and
multiple sclerosis—though the precise constellation of patterns
observed with these biomarkers may differ in each. However, the
specific panel that we have identified here are likely to be helpful
as objective markers for diagnosing CFS, determining subgroups,
following patients over time and as targets for therapeutic
strategies. These indicators are parts of a complex and integrated
system and their inter-dependency must be addressed [46].
Accordingly, we are currently engaged in mapping the network
structure of neuroendocrine-immune interaction in CFS
Limitations
Obvious limitations of this study are that each patient sample
represents a single point in time. To address this, we are
conducting a large longitudinal study to follow 150 subjects over
18 months. Samples are collected during times of relative
symptom remission and exacerbation. Completion of the study
will allow the correlation of CFS related symptoms with
lymphocyte function and activation. Because CFS is a condition
that affects women in disproportionate numbers, over eighty
percent of the cases in the present study were female. The larger
study will have sufficient power to allow a sub study of biomarker
patterns in men with CFS.
Conclusions
The predominance of evidence indicating that people with CFS
have decreased function of NK cells and abnormal activation of T
and NK cells was supported by this study. The purpose of the
study was to determine usefulness of these measurements as
biomarkers. By ROC analysis, NKCC and dipeptidyl peptidase/
CD26 were identified as potential biomarkers for CFS through
their demonstrated accuracy in discriminating CFS patients from
healthy controls. Dipeptidyl peptidase/CD26 on lymphocytes or
in serum was not correlated with NKCC, suggesting that these are
non-redundant biomarkers. Current CFS treatments are directed
at reducing symptom severity but no cure exists for this condition.
The findings of this study give support to the concept that cause
and/or the pathophysiology of CFS are related to infection. These
findings may lead to therapeutic approaches. The specter of
Figure 4. ROC analyses were used to evaluate relative number
of molecules of dipeptidyl peptidase IV/CD26 on the surface of
CD2+ lymphocytes as a predictor of CFS. The nonparametric ROC
plot (orange curve) indicated the ability of number of molecules of
dipeptidyl peptidase IV/CD26 on the surface of CD2+ lymphocytes to
discriminate between CFS cases and healthy controls. Smaller values
were associated with CFS cases. The 45 degree line (green) indicates the
theoretical plot of a test with no discrimination between CFS and
controls. cell at saturating concentrations of antibody; rMol/cell) is
shown.
doi:10.1371/journal.pone.0010817.g004
Biomarkers in CFS
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10817infectious disease further emphasizes the significance of this
research to public health.
Supporting Information
Figure S1 Illustration of technique used to convert fluorescence
intensity values to median numbers of molecules PE bound per cell
(relative numbers of molecules protein expressed per cell at
saturating concentrations of antibody; rMol/cell).
Found at: doi:10.1371/journal.pone.0010817.s001 (0.38 MB TIF)
Table S1 Coordinates of the Curve for NKCC.
Found at: doi:10.1371/journal.pone.0010817.s002 (0.23 MB
DOC)
Table S2 Coordinates of the ROC Curve for CD26+CD2+
Lymphocytes in CFS Compared to Controls.
Found at: doi:10.1371/journal.pone.0010817.s003 (0.20 MB
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Table S3 Coordinates of the ROC curve for sCD26.
Found at: doi:10.1371/journal.pone.0010817.s004 (0.17 MB
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Table S4 Coordinates of the curve for rMolCD26CD2+.
Found at: doi:10.1371/journal.pone.0010817.s005 (0.28 MB
DOC)
Author Contributions
Conceived and designed the experiments: MAAF KM NGK. Performed
the experiments: XRZ KM. Analyzed the data: MAAF GJB. Contributed
reagents/materials/analysis tools: SL BH MA. Wrote the paper: MAAF
NGK. Critically reviewed paper: BH, MA, GJB.
References
1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins, et al. (1994) The chronic
fatigue syndrome: a comprehensive approach to its definition and study.
International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:
953–9.
2. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, et al. (2003)
Identification of ambiguities in the 1994 chronic fatigue syndrome research case
definition and recommendations for resolution. BMC Health Serv Res 3(1): 25.
Review.
3. Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, et al. (2003)
Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch
Intern Med 163: 1530–1536.
4. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, et al. (1999)
A community-based study of chronic fatigue syndrome. Arch Intern Med 159:
2129–2137.
5. Chandler HK, Ciccone D, MacBride RJ, Natelson B (2008) Medically
unexplained illness in short- and long-term disability applicants: prevalence
and cost of salary reimbursement. Disabil Rehabil 30(16): 1185–1191.
6. Reynolds KJ, Vernon SD, Bouchery E, Reeves WC (2004) The economic
impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2(1): 4.
7. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S (2008) The
economic impact of ME/CFS: Individual and societal costs. Dyn Med 7: 6.
8. Gerrity TR, Bates J, Bell DS, Chrousos G, Furst G, et al. (2003) Chronic fatigue
syndrome: what role does the autonomic nervous system play in the
pathophysiology of this complex illness? Neuroimmunomodulation 10: 134–141.
9. Hurwitz BE, Coryell VT, Parker M, Martin P, Laperriere A, et al. Chronic
fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence
of diminished cardiac function. Clin Sci (Lond), 2009 Oct 19;, 118(2): 125–35.
10. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S (2006) Causes of
death among patients with chronic fatigue syndrome. Health Care Women Int
27: 615–26.
11. Levine PH, Peterson D, McNamee FL, O’Brien K, Gridley G, et al. (1992) Does
chronic fatigue syndrome predispose to non-Hodgkin’s lymphoma? Cancer Res
52(19 Suppl): 5516s–5518s.
12. Evenga ˚rd B, Jonzon E, Sandberg A, Theorell T, Lindh G (2003) : Differences
between patients with chronic fatigue syndrome and with chronic fatigue at an
infectious disease clinic in Stockholm, Sweden. Psychiatry Clin Neurosci 57:
361–368.
13. Jason LA, Plioplys AV, Torres-Harding S, Corradi K (2003) Comparing
symptoms of chronic fatigue syndrome in a community-based versus tertiary
care sample. J Health Psychol 8: 459–64.
14. Klimas NG, Morgan R, Salvado F, Fletcher MA (1990) Immunologic
abnormalities of chronic fatigue syndrome. J Clin Microbiol 28: 1403–1410.
15. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA (1994) Immunologic
abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 18 Suppl
1: S136–41.
16. Landay AL, Jessop C, Lennette ET, Levy JA (1991) Chronic fatigue syndrome:
clinical condition associated with immune activation. Lancet 338: 707–12.
17. Maher K, Klimas NG, Fletcher MA (2003) Immunology. In Handbook of
Chronic Fatigue edited by Jason LA, Fennell PA, Taylor RR. Hoboken, NJ:
John Wiley & Sons. pp 124–151.
18. Lyall M, Peakman M, Wessely S (2003) A systematic review and critical
evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 55:
79–90. Review.
19. Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, et al. (1987)
Phenotypic and functional deficiency of natural killer cells in patients with
chronic fatigue syndrome. J Immunol 139: 3306–3313.
20. Maher KJ, Klimas NG, Fletcher MA (2005) Chronic fatigue syndrome is
associated with diminished intracellular perforin. Clin Exp Immunol 142:
505–511.
21. Raison CL, Lin JM, Reeves WC (2009) Association of peripheral inflammatory
markers with chronic fatigue in a population-based sample. Brain Behav Immun
23: 327–337.
22. Aspler AL, Bolshin C, Vernon SD, Broderick G (2008) Evidence of
inflammatory immune signaling in chronic fatigue syndrome: A pilot study of
gene expression in peripheral blood. Behav Brain Funct, Sep 26; 4: 44.
23. Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, et al. (2006)
Impaired natural immunity, cognitive dysfunction, and physical symptoms in
patients with chronic fatigue syndrome: preliminary evidence for a subgroup?
J Psychosom Res 60: 559–566.
24. Fletcher MA, Baron G, Fischl M, Klimas NG (1987) Use of whole blood
methods in assessment of immune parameters in immunodeficiency states. Diag
Clin Immunol 5: 69–81.
25. Maher K, Fletcher MA (2006) Quantitative flow cytometry in the clinical
laboratory, Clin. Appl Immunol Rev 5: 353–372.
26. Zweig MH, Campbell G (1993) Receiver-Operating Characteristic (ROC) plots:
A fundamental evaluation tool in Clin Med Clin Chem. 39: 561–577.
27. Evenga ˚rd B, Klimas N (2002) Chronic fatigue syndrome: Probable pathogenesis
and possible treatments. Drugs 62: 2433–2446.
28. Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, et al. (2006)
Use of valganciclovir in patients with elevated antibody titers against Human
Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing
central nervous system dysfunction including long-standing fatigue. J Clin Virol
37: Suppl 1: S33–38.
29. Glaser R, Padgett DA, Litsky ML, Baiocchi RA, Yang EV, Chen M, et al. (2005)
Stress-associated changes in the steady-state expression of latent Epstein-Barr
virus: implications for chronic fatigue syndrome and cancer. Brain Behav
Immun 19: 91–103.
30. Ledina D, Bradaric ´ N, Milas I, Ivic ´ I, Brncic ´ N, et al. (2007) Chronic fatigue
syndrome after Q fever. Med Sci Monit 13: CS88–92.
31. DeFreitas E, Hilliard B, Cheney PR, Bell DS, Kiggundu E, et al. (1991)
Retroviral sequences related to human T-lymphotropic virus type II in patients
with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci U S A
88: 2922–6.
32. Khan AS, Heneine WM, Chapman LE, Gary HE, Jr., Woods TC, et al. (1993)
Folks TM, Schonberger LB. Assessment of a retrovirus sequence and other
possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med
118(4): 241–5.
33. Holmes MJ, Diack DS, Easingwood RA, Cross JP, Carlisle B (1997) Electron
microscopic immunocytological profiles in chronic fatigue syndrome. J Psychiatr
Res 31: 115–2.
34. Lombardi VC, Ruscetti FW, Gupta JD, Pfost MA, Hagen KS, et al. (2009)
Detection of infectious retrovirus, XMRV, in blood cells of patients with chronic
fatigue syndrome. Science 326: 585–589.
35. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, et al. (2010) Failure to
Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome. PLoS One,
2010 Jan 6; 5(1): e8519.
36. Glaser R, Litsky ML, Padgett DA, Baiocchi RA, Yang EV, et al. (2006) EBV-
encoded dUTPase induces immune dysregulation: Implications for the
pathophysiology of EBV-associated disease. Virology 346: 205–218.
37. Yang SS, Fu LS, Chang CS, Yeh HZ, Chen GH, et al. (2006) Changes of soluble
CD26 and CD30 levels correlate with response to interferon plus ribavirin
therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 21:
1789–93.
38. Ibegbu CC, Xu YX, Fillos D, Radziewicz H, Grakoui A, et al. (2009)
Differential expression of CD26 on virus-specific CD8(+) T cells during active,
latent and resolved infection. Immunology 126: 346–53. Epub 2008 Jul 22.
39. Busso N, Wagtmann N, Herling C, Chobaz-Pe ´clat V, Bischof-Delaloye A, et al.
(2005) Circulating CD26 is negatively associated with inflammation in human
and experimental arthritis. Am J Pathol 166: 433–42.
Biomarkers in CFS
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e1081740. Muscat C, Bertotto A, Agea E, Bistoni O, Ercolani R, et al. (1994) Expression
and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid
T cells in rheumatoid arthritis patients. Clin Exp Immunol 98(2): 252–256.
41. Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of
dipeptidyl-peptidase-4 (DPP-4) Best Pract Res Clin EndocrinolMetab. 223:
479–486.
42. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Emerging role of
dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc
Health Risk Manag 4: 753–768.
43. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type
2 diabetes: systematic review and meta-analysis. JAMA 11;298: 194–206.
44. Yan S, Marguet D, Dobers J, Reutter W, Fan H (2003) Deficiency of CD26
results in a change of cytokine and immunoglobulin secretion after stimulation
by pokeweed mitogen. Eur J Immunol. 33: 1519–527.
45. Straburzynska-Lupa A, Nowak A, Pilaczynska-Szczesniak L, Straburzynska-
Migaj E, Romanowski W, et al. (2010) Visfatin, resistin, hsCRP and insulin
resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Clin Exp Rheumatol 2010 28(1): 19–24.
46. Fuite J, Vernon SD, Broderick G (2008) Neuroendocrine and immune network
re-modeling in chronic fatigue syndrome: an exploratory analysis. Genomics 92:
393–399.
Biomarkers in CFS
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10817